Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 48 of 6351
-
Can a new drug combo outsmart triple-negative breast cancer?
Disease control Not yet recruitingTo investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.
Phase 2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can an oral chemo pill boost breast cancer treatment?
Disease control Recruiting nowThis is a multicenter, open-label, dose-finding trial using a backfill Bayesian optimal interval (BF-BOIN) design to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for paclitaxel oral solution combined with anti-HER2 treatment. Eligible HER2-pos…
Phase 1/2 • Sponsor: Liu Shu • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Daily pill aims to stop chronic migraine before it starts
Prevention Not yet recruitingRimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant …
Phase 3 • Sponsor: Pfizer • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Could a shot replace daily HIV pills? new trial tests injectable combo
Disease control Recruiting nowThe study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B. The goal of Phase 2, Part A is to assess the effectiveness of study drugs GS-3242 plus Lenacapavir (LEN) versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide …
Phase 2/3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
New drug shows promise for sustained weight loss in type 2 diabetes
Disease control Recruiting nowThe primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets stubborn colorectal cancer mutation
Disease control Recruiting nowThis study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new pill quiet the mind? a large trial puts it to the test
Disease control Recruiting nowThis is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per day \[mg/day\]) to placebo in adults at least 18 yea…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells take on lupus kidney disease
Disease control Recruiting nowThe primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the prop…
Phase 2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill takes on tough lung cancer mutation
Disease control Recruiting nowThe purpose of this study is to compare the effectiveness, safety and tolerability of GFH375 versus docetaxel in participants with KRAS G12D-mutant non-small cell lung cancer (NSCLC). GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G…
Phase 3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Four-Pronged attack beat brain lymphoma?
Disease control Recruiting nowThis prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly diagnosed primary central nervous system diffuse large B-ce…
Phase 2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Tailored radiation aims to shrink tumors, spare healthy tissue in nasopharyngeal cancer
Disease control Recruiting nowThis is a non-inferiority, multicenter, randomized phase 3 trial aimed to evaluate whether primary clinical target volume (CTVp) delineation based on margin expansion provides comparable outcomes compared with the consensus CTVp approach based on margin expansion and the stepwise…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could atomoxetine or metformin be the next Alzheimer's treatment?
Disease control Recruiting nowA multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzh…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Nasal spray could offer new hope for Treatment-Resistant depression
Disease control Recruiting nowThe purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder …
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New weight-loss drug aims for lasting results in large phase 3 trial
Disease control Recruiting nowThe primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
Disease control Not yet recruitingThis Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a …
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug aims to stop liver failure in MASH cirrhosis
Disease control Recruiting nowThis study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?
Vaccine Recruiting nowThis study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for …
Phase 1/2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jul 31, 2026 00:00 UTC
-
New pill targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug aims to reverse liver scarring in MASH cirrhosis
Disease control Recruiting nowThis is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusio…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC